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In this work we provide a theoretical explanation for the observations that: (i) young animals are more 
resistant to hypoxia than adult ones and (ii) repeated exposure to a hypoxic insult increases the tolerance 
of young animals and isolated brain tissue to that insult. Considered here is the role of taurine, a putative 
Ca 2+ transport modulator, in attenuating Ca 2+ influx and overload in brain tissue upon hypoxia. It is pro- 
posed that the higher resistance of young animals to hypoxia stems from their higher brain content of tau- 
rine as compared with adults. The increased resistance to lack of oxygen upon re-exposure to hypoxia may 
occur as a result of protein and coenzyme A (CoA) breakdown which leads to the accumulation of products 
like cystine, cysteine, cysteamine and other sulfur-containing compounds. Upon reoxygenation, these com- 
pounds are oxidized to form taurine, which in turn attenuates neuronal Ca 2+ accumulation. The sulfur- 
containing compounds are considered to be natural scavengers of oxygen-derived free radicals which are 
formed upon reoxygenation and have been implicated as a major component in the process leading to 
ischemic/hypoxic brain damage. Repeated hypoxic insults bring about the formation of higher levels of tau- 
rine and hence the observed adaptation to oxygen lack. The hypothesis presented here is supported by exper- 
imental observations in our laboratory and those of others. 
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1. INTRODUCTION 
It is common knowledge that the tissue of  mam- 
mal ian central nervous system (CNS) is one of  the 
most sensitive to any type of  hypoxia.  Oxygen lack 
can trigger biochemical  as well as functional and 
structural  changes, their intensity and local izat ion 
depending on the phylogenic and ontogenic ma- 
tur i ty of  the CNS and the intensity of  the hypoxic 
insult [1]. The higher resistance of  immature 
animals than adults to hypoxia,  anoxia, radial  ac- 
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celeration and bleeding [2-11] is yet to be explain- 
ed. The better adaptabi l i ty  of  young animals than 
mature  ones to l imited supplies of  oxygen, 
especial ly where brain tissue is concerned [12-14], 
is also unexplained. Yet, as our knowledge of  the 
mechanisms involved in hypoxic brain damage in- 
creases, a pharmacological  t reatment or preven- 
t ion of  such damage as part of  future therapy 
appears to be feasible [15-17]. As a result o f  the 
rapid fall in ATP  levels and energy charge (EC) 
upon hypoxia,  Ca 2+ homeostasis cannot be main- 
tained, leading to Ca z+ over load and irreversible 
neuronal  damage [18]. Oxygen-derived free 
radicals have been impl icated in the causat ion of  
hypoxic brain damage,  via l ipid peroxidat ion,  as 
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they are formed upon reperfusion/reoxygenation 
[19-22]. Recently we have shown that the 
resistance of adult rat brain tissue to hypoxia in 
vitro increases by exposure to lack of oxygen [23]. 
Using the same preparation, we have also 
demonstrated taurine's ability to protect neuronal 
tissue against hypoxic damage [24]. The ex- 
tracellular level of taurine has been shown to in- 
crease in the hippocampus of rabbits after 
ischemia [25]. Taurine is believed to modulate 
Ca z+ transport across biomembranes [26,27]. In 
situ, taurine is synthesized via sulfur-containing 
compounds like cystine, cysteine, cysteic acid, 
cysteamine and hypotaurine [28,29]. 
The following hypothesis i based on experimen- 
tal data and biological knowledge. It provides an 
explanation for both the higher resistance and the 
better adaptability of young animals to hypoxia as 
compared to adults. We postulate the existence of 
an endogenous protective mechanism against 
hypoxic damage in brain and possibly in other 
tissues too. While active in young animals, this 
mechanism is dormant in adults, where it can be 
activated by repeated exposure to lack of oxygen. 
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Fig.1. A hypothesis on the formation of taurine from 
sulfur-containing amino acids and amines upon 
hypoxia/ischemia and reoxygenation. See text for 
details. 
2. HYPOTHESIS  
While scanning the literature on the develop- 
ment of resistance to hypoxia in young animals 
and their adaptability to oxygen deprivation, on 
the one hand, and articles on the biosynthesis and 
functions of taurine, on the other, we noticed that 
the postnatal decrease in brain taurine levels 
[30,31] coincides with the postnatal decrease in 
resistance of animals to hypoxia [2-11]. Both 
resistance to hypoxia and taurine's brain levels are 
high in neonates and fall rapidly as animals 
mature. It therefore seems reasonable to 
hypothesize that the higher levels of taurine in 
young animals are the reason for the higher 
tolerance to hypoxia. Adaptation to hypoxia could 
be the result of an increase in the usually low levels 
of taurine, triggered by a hypoxic event. Fig.1 
depicts our hypothesis on resistance and adapta- 
tion to hypoxia as follows: a hypoxic (or ischemic) 
insult halts the aerobic energy production and 
reduces ATP levels and EC to a minimum. 
Anaerobic glycolysis and low levels of ATP cannot 
support ion homeostasis and protein synthesis. 
This results in Ca z+ and Na + influx, K + efflux and 
protein breakdown which brings about the ac- 
cumulation of cystine and cysteine. Also 
postulated is the breakdown of coenzyme A (CoA) 
or, alternatively, the halting of its production and 
the accumulation of some of its precursors, like p- 
pantothenyl cysteine, p-pantetheine and cyste- 
amine. While at the initial stages of the hypoxic in- 
sult ion fluxes are reversible, extended periods of 
oxygen deprivation result in intracellular Ca 2+ ac- 
cumulation and irreversible damage. Reoxygena- 
tion, while supplying the most needed oxygen, 
increases tremendously the production of oxygen- 
derived free radicals which lead to membrane 
damage through lipid peroxidation and further in- 
crease in the accumulation of Ca 2÷ (overload). 
Concomitantly, the products of protein and CoA 
breakdown are oxidized to form taurine via in- 
termediates like cysteine sulfinic acid, cysteic acid 
and hypotaurine. As they are being oxidized, these 
products act as scavengers of oxygen-derived free 
radicals, reducing the amount of, and the damage 
elicited by, the latter. Taurine, once formed, acts 
directly on the neuronal membrane to attenuate 
Ca 2÷ influx and/or overload. 
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3. DISCUSSION 
The proposed hypothesis explains the higher 
resistance of young animals to hypoxia as com- 
pared with adults and the mechanism by which 
adaptation to lack of oxygen may occur. There are 
many published observations in the literature to 
support the above-mentioned hypothesis. Firstly, 
where the biosynthesis of taurine is concerned, it 
has been shown that hypotaurine can account for 
the metabolic origin of taurine [32]. Secondly, 
hypotaurine with its sulfinate moiety is an obvious 
oxidizable molecule, which is the basis of its an- 
tioxidant properties [32]. It has been proposed that 
hypotaurine plays a unique role as an oxygen-free 
radical trap in tissues; when oxygen free radicals 
are generated they may react with hypotaurine to 
extract an electron to form the resonance- 
stabilized hypotaurine radical and a hydroxide ion. 
Two hypotaurine radicals can next unite to form 
the intermediate disulfone which can rearrange in 
an internal oxidation-reduction to generate one 
molecule of taurine and one of hypotaurine [32]. 
The oxidation reaction is dependent on 
nicotinamide-adenine dinucleotides and divalent 
cations and can be stimulated, to a certain extent, 
by superoxide dismutase and inhibited by catalase 
[32,33]. Hypotaurine itself is formed via the cys- 
teine sulfinic acid and the cysteic acid pathways 
[34]. In some organs, such as the kidney, taurine 
can be synthesized via the cysteamine pathway 
[28,34-36]. Hypotaurine and taurine have been 
shown to protect against light-induced amage to 
rod outer segments (ROS) of the frog eye in vitro 
[37]. Exposure of isolated ROS to continuous light 
of an intensity of about 5000 lux for 2 h resulted 
in marked ROS swelling, with extensive disruption 
of the architecture of lamellar discs in most of the 
segments. Addition of taurine provided a complete 
protection against the deleterious effect of light, 
preserving ROS structure in better condition than 
those kept in the dark [37]. Only hypotaurine x- 
hibited an effect similar to that of taurine [37]. The 
involvement of lipid peroxidation processes in the 
light-induced damage to photoreceptors i  well- 
documented [37-39]. Taurine protected mem- 
brane structure of illuminated ROS and at the 
same time prevented the increase in lipid peroxida- 
tion induced by light. Hypotaurine, the only other 
amino acid to exhibit an ability to reduce lipid 
peroxidation, was found to be even more effective 
than taurine [37]. Similar findings were reported 
for rabbit sperm motility which is impaired by ox- 
idative reactions; both taurine and hypotaurine 
were efficacious in preserving cell motility and at 
the same time suppressing lipid peroxidation [40]. 
The capacity of hypotaurine to quench oxygen- 
derived free radicals generated by the xanthine ox- 
idase system in the presence of EDTA-Fe 2+ has 
also been shown [32]. Frog retinal taurine levels 
significantly decrease or increase following 3-6 
weeks of light or dark adaptation, respectively 
[41]. 
Much evidence is available as to the role of 
taurine in the regulation of calcium homeostasis n
excitable tissues, including our own studies using 
the hippocampal s ice preparation (fig.2) [24]. The 
decline in the evoked population spike (synaptic 
function) amplitude upon Ca 2+ depletion from the 
bathing medium was attenuated by pretreatment 
of the hippocampal slices with I mM taurine. In 
the myocardium taurine has been shown to slow 
the washout of calcium from isolated heart 
preparations exposed to buffers lacking calcium 
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Fig.2. Changes in the amplitude of evoked population 
responses in rat hippocampal slices. Experimental s ices 
(o) were perfused with 1 mM taurine (A) 30 min before 
perfusing both these slices and the control ones (o) with 
a medium containing 0 mM Ca 2+ (B). 40 min later the 
perfusion medium was changed back to a 
CaZ+-containing medium (C). Taurine attenuated the 
fall in the population spike amplitude by slowing the 
washout of Ca 2+ from the experimental hippocampal 
slices as compared to control ones. For more details see 
[24]. 
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[42,43] and to reverse the negative inotropic effects 
of reduced perfusate calcium and exposure to 
calcium antagonists [44]. Taurine also prevents 
myocardial necrotic lesions associated with 
calcium overload [45-47]. Accumulation of 45Ca 
by retinal subcellular fractions isolated from the 
chick retina was decreased when taurine was pre- 
sent in the incubation medium [48]. Similar results 
were obtained using a sarcolemma preparation [49] 
and in synaptosomes [50]. With regard to the 
physiological role of taurine, stroke-prone spon- 
taneously hypertensive rats (SHR) have been 
shown to have significantly reduced levels of 
taurine in their liver and serum [51]. Recently, a 
significant decrease in hypothalamic ontent of 
taurine in SHR was found [34]. Taurine shows a 
protective effect against a wide variety of con- 
vulsive states, with very different etiologies 
[52,53]. It has been shown that the anticonvulsant 
effect of taurine against metrazol requires the 
presence of free calcium [54]. Taurine also an- 
tagonizes 4-aminopyridine-induced s izures, which 
are probably caused by increased calcium entry in- 
to the nerve terminal [55]. 
The above mentioned observations are all in 
support of our proposed hypothesis on the role of 
taurine in the protection of neuronal tissue against 
hypoxic damage and adaptation to lack of oxygen. 
Lehmann and his colleagues [56] reported that the 
fall in extracellular Ca 2+ upon decapitation 
ischemia is brought about by Ca z+ influx. This fall 
could be prevented by taurine. The same authors 
also measured a 25-fold increase in the initial levels 
of taurine following complete cerebral ischemia in 
the rabbit [25,56]. 
Thus, in both young and hypoxia-adapted 
animals, higher CNS taurine levels would provide 
the observed resistance to hypoxia by attenuating 
Ca z+ influx and/or overload which is triggered by 
lack of oxygen. Young animals should exhibit bet- 
ter adaptability to hypoxia than adults due to their 
initial higher CNS levels of taurine. In addition, 
the long time required for adaptation to hypoxia in 
vitro [24] and the slow decline (days) in the 
resistance to hypoxia in newborn rats [57] could be 
due to the slow turnover of taurine. Our 
hypothesis predicts that animals with inherently 
low levels of taurine or those in which taurine 
biosynthesis i defective, will be highly sensitive to 
hypoxia. Inversely, animals with high resistance to 
LETTERS November 1987 
lack of oxygen might contain high brain levels of 
taurine. 
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